Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$1.23
+2.5%
$1.42
$0.77
$8.65
$220.64M0.736.40 million shs13.60 million shs
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
$3.85
-3.3%
$3.97
$2.74
$7.28
$72.79M0.5916,878 shs21,742 shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.43
+13.4%
$4.25
$2.76
$6.00
$225.77M0.4115,482 shs20,304 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$2.20
+2.8%
$1.82
$1.07
$4.62
$225.15M0.36658,155 shs206,278 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Canopy Growth Corporation stock logo
CGC
Canopy Growth
+2.50%+8.85%-27.65%+36.96%-80.35%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-3.27%+0.79%-23.15%-0.26%+19.20%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
+14.41%+12.54%+15.29%+66.31%+2.45%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
+2.80%+9.45%+15.18%+83.33%+32.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Canopy Growth Corporation stock logo
CGC
Canopy Growth
2.8287 of 5 stars
2.53.00.00.02.80.01.3
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
1.8488 of 5 stars
3.53.00.00.00.61.70.0
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
1.6739 of 5 stars
3.33.00.00.01.10.00.6
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.1184 of 5 stars
3.63.00.00.03.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1.00
Sell$2.0062.60% Upside
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
3.00
Buy$25.00549.35% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0047.33% Upside
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3.13
Buy$8.00263.64% Upside

Current Analyst Ratings Breakdown

Latest GNTA, CGC, PRQR, and NBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$8.00
5/30/2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight
5/13/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.00
4/29/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$8.00
4/29/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$225.65M1.00N/AN/A$1.90 per share0.65
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/A$0.74 per shareN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M6.53N/AN/A($1.51) per share-3.60
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$20.46M11.31N/AN/A$0.91 per share2.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$429.86M-$4.04N/AN/AN/A-195.76%-88.54%-40.78%8/8/2025 (Estimated)
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-$9.64MN/A0.00N/AN/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)

Latest GNTA, CGC, PRQR, and NBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q4 2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million
5/8/2025Q1 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Canopy Growth Corporation stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.62
3.12
2.10
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/A
6.89
6.89
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3.33%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
15.13%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%

Insider Ownership

CompanyInsider Ownership
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1.30%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
28.99%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3,150183.87 million181.48 millionOptionable
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
718.29 million12.99 millionNot Optionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.21 million96.38 millionOptionable

Recent News About These Companies

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance
Cantor Fitzgerald Comments on PRQR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$1.23 +0.03 (+2.50%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.26 +0.03 (+2.44%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Genenta Science stock logo

Genenta Science NASDAQ:GNTA

$3.85 -0.13 (-3.27%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$4.00 +0.15 (+3.87%)
As of 07/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.43 +0.64 (+13.36%)
Closing price 07/8/2025 03:42 PM Eastern
Extended Trading
$5.42 -0.01 (-0.18%)
As of 07/8/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$2.20 +0.06 (+2.80%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.16 -0.04 (-1.64%)
As of 07/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.